Jazz Pharmaceuticals plc (JAZZ) surged 21.59%, closing at $171.52, up $30.45, after announcing the Phase 3 HERIZON-GEA-01 trial of its drug Ziihera (zanidatamab-hrii) plus chemotherapy, with or without tislelizumab, showed statistically significant improvements in both progression-free survival - PFS and overall survival - OS versus trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma.
The company plans to submit a supplemental Biologics License Application - sBLA in the first half of 2026. On the same day, Jazz also showcased new clinical and translational data across its pipeline, highlighting advances in HER2-targeted therapies and neuro-oncology assets, underscoring its expanding oncology platform.
JAZZ experienced unusually heavy trading volume as investors absorbed the trial results and pipeline momentum. The stock's 52-week range is $89.34 - $172.10.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.